1. Home
  2. LEXX vs XGN Comparison

LEXX vs XGN Comparison

Compare LEXX & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • XGN
  • Stock Information
  • Founded
  • LEXX 2004
  • XGN 2002
  • Country
  • LEXX Canada
  • XGN United States
  • Employees
  • LEXX N/A
  • XGN N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • XGN Medical Specialities
  • Sector
  • LEXX Health Care
  • XGN Health Care
  • Exchange
  • LEXX Nasdaq
  • XGN Nasdaq
  • Market Cap
  • LEXX 49.3M
  • XGN 49.4M
  • IPO Year
  • LEXX N/A
  • XGN 2019
  • Fundamental
  • Price
  • LEXX $3.19
  • XGN $3.03
  • Analyst Decision
  • LEXX Strong Buy
  • XGN Buy
  • Analyst Count
  • LEXX 2
  • XGN 1
  • Target Price
  • LEXX $11.00
  • XGN $7.00
  • AVG Volume (30 Days)
  • LEXX 96.5K
  • XGN 33.7K
  • Earning Date
  • LEXX 11-18-2024
  • XGN 11-11-2024
  • Dividend Yield
  • LEXX N/A
  • XGN N/A
  • EPS Growth
  • LEXX N/A
  • XGN N/A
  • EPS
  • LEXX N/A
  • XGN N/A
  • Revenue
  • LEXX $411,019.00
  • XGN $56,660,000.00
  • Revenue This Year
  • LEXX $82.02
  • XGN $9.98
  • Revenue Next Year
  • LEXX $95.09
  • XGN $13.63
  • P/E Ratio
  • LEXX N/A
  • XGN N/A
  • Revenue Growth
  • LEXX 34.05
  • XGN 7.05
  • 52 Week Low
  • LEXX $0.85
  • XGN $1.30
  • 52 Week High
  • LEXX $6.85
  • XGN $3.71
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 48.73
  • XGN 53.18
  • Support Level
  • LEXX $2.91
  • XGN $2.90
  • Resistance Level
  • LEXX $3.39
  • XGN $3.18
  • Average True Range (ATR)
  • LEXX 0.20
  • XGN 0.17
  • MACD
  • LEXX 0.00
  • XGN -0.02
  • Stochastic Oscillator
  • LEXX 56.00
  • XGN 65.12

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: